"Across five positive Phase III studies, Retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health," said Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health
And what did we see?" said Drucker
In 2024 the Food and Drug Administration added cardiovascular risk as a reason to be prescribed the GLP-1 drug Wegovy, grounded in results from a major trial that showed fewer heart attacks, strokes, and cardiovascular deaths in adults with obesity or overweight and established heart disease
Patient-First Approach We believe that semaglutide therapy is most successful when patients feel heard, supported, and empowered
Over-the-counter medications such as antacids may provide relief for dyspepsia, but always consult your pharmacist or GP before adding new medications